Slate Path Capital LP Holds 357,880 Shares of Cyclerion Therapeutics

TL;DR

**Slate Path Capital still owns 357,880 shares of Cyclerion, signaling continued institutional interest.**

AI Summary

Slate Path Capital LP, a Delaware-based investment firm, filed an amended SC 13G/A on January 22, 2024, disclosing its beneficial ownership in Cyclerion Therapeutics, Inc. As of December 31, 2023, Slate Path Capital LP holds shared voting and dispositive power over 357,880 shares of Cyclerion's common stock. This filing indicates a significant institutional stake, which could influence the stock's perception among investors, as large holders often signal confidence or concern.

Why It Matters

This filing shows a major institutional investor, Slate Path Capital LP, maintains a significant stake in Cyclerion Therapeutics, which can be seen as a vote of confidence or a strategic position.

Risk Assessment

Risk Level: low — This filing is an amendment to a previous disclosure and indicates a stable institutional holding, not a new, volatile event.

Analyst Insight

Investors should note that a significant institutional holder like Slate Path Capital LP maintains its position, suggesting continued interest in Cyclerion Therapeutics. This could be a factor to consider when evaluating the stock, but further research into Cyclerion's fundamentals and Slate Path's investment thesis would be prudent.

Key Numbers

• 357,880 — Shares Beneficially Owned (Represents the total number of Cyclerion Therapeutics common stock shares Slate Path Capital LP has shared voting and dispositive power over as of December 31, 2023.)

Key Players & Entities

• Slate Path Capital LP (company) — the reporting person and beneficial owner
• Cyclerion Therapeutics, Inc. (company) — the subject company whose securities are being reported
• 357,880 (dollar_amount) — the aggregate amount of shares beneficially owned
• December 31, 2023 (date) — the date of the event requiring the filing
• Delaware (company) — place of organization for Slate Path Capital LP

Forward-Looking Statements

• Slate Path Capital LP will maintain its significant stake in Cyclerion Therapeutics for the foreseeable future. (Slate Path Capital LP) — medium confidence, target: Q2 2024

FAQ

Filing Documents

• p24-0104sc13ga.htm (SC 13G/A) — 58KB
• 0000902664-24-000479.txt ( ) — 59KB

(a)

Item 1(a). NAME OF ISSUER: The name of the issuer is Cyclerion Therapeutics (the " Company ").

(b)

Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: The Company's principal executive offices are located at 245 First Street, 18th Floor, Cambridge, Massachusetts 02142.

(a)

Item 2(a). NAME OF PERSON FILING: This statement is filed by: (i) Slate Path Capital LP (the " Investment Manager "), a Delaware limited partnership and the investment manager to certain funds (the " Slate Path Funds "), with respect to the shares of Common Stock (as defined in Item 2(d) below) directly held by the Slate Path Funds; and (ii) David Greenspan (" Mr. Greenspan "), the managing partner of Jades GP, LLC, a Delaware limited liability company and the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Slate Path Funds. The foregoing persons are hereinafter sometimes collectively referred to as the " Reporting Persons ." The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.

(b)

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: The address of the business office of each of the Reporting Persons is 717 Fifth Avenue, 16 th Floor, New York, NY 10022.

(c)

Item 2(c). CITIZENSHIP: The Investment Manager is a Delaware limited partnership. Mr. Greenspan is a citizen of the United States.

(d)

Item 2(d). TITLE OF CLASS OF SECURITIES: Common Stock, no par value (the " Common Stock ").

(e)

Item 2(e). CUSIP NUMBER: 23255M204 CUSIP No. 23255M204 13G/A Page 5 of 7 Pages Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) ¨ Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) x Parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) ¨ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) ¨ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentages set forth herein are calculated based upon 2,445,096 shares of Common Stock outstanding as of November 9, 2023, as reported by the Company in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed with the Securities and Exchange Commission on November 13, 2023. Item 5. Not applicable. CUSIP No. 2

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct. DATED: January 22, 2024 SLATE PATH CAPITAL LP By: Jades GP, LLC, its General Partner By: /s/ John Metzner Name: John Metzner Title: Chief Operating Officer /s/ Jim Feeney as Attorney-In-Fact* DAVID GREENSPAN

View Full Filing

View this SC 13G/A filing on SEC EDGAR